Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B-lymphocyte antigen CD20 (CD20)
- Target
- CD20
- Molecular classification
- Membrane protein, Tetraspan protein, Receptor
01
Overview
CD20, also known as MS4A1, is a non-glycosylated phosphoprotein expressed on the surface of B lymphocytes from the pre-B cell stage through mature B cells. It is a key regulator of B-cell development, differentiation, and BCR signaling. As a therapeutic target, it is engaged by monoclonal antibodies like rituximab to deplete B cells in B-cell malignancies and autoimmune diseases. CD20 does not internalize or shed upon antibody binding, making it an effective target for complement-mediated cytotoxicity.
- Other names
- MS4A1
02
Mechanism of action
Antibody binding induces clustering/capping of CD20, promoting complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), leading to B-cell depletion.
03
Biological functions
B-cell developmentB-cell differentiationB-cell receptor signalingRegulation of B-cell activationHumoral immune responseMaintenance of B-cell resting state
04
Disease associations
Non-Hodgkin lymphomaChronic lymphocytic leukemiaRheumatoid arthritisAutoimmune disorders
05
Safety considerations
Infusion reactionsTumor lysis syndromeProgressive multifocal leukoencephalopathy (PML)Hepatitis B virus reactivationHypogammaglobulinemiaIncreased risk of infection
06
Interacting drugs
Rituximab
2 more in the full profile.
07
Biomarkers
CD20 expression level on B cells (for patient selection)B-cell count (for monitoring treatment efficacy)
Beyond the preview
Go deeper on B-lymphocyte antigen CD20 (CD20).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B-lymphocyte antigen CD20 (CD20).